Home/Pipeline/3K3A-APC

3K3A-APC

Ischemic Stroke

Phase 2/3Active

Key Facts

Indication

Ischemic Stroke

Phase

Phase 2/3

Status

Active

Company

ZZ Biotech

About ZZ Biotech

ZZ Biotech is a clinical-stage biotech firm developing 3K3A-APC, a genetically engineered variant of human activated protein C (APC) optimized for therapeutic use. Its lead program targets ischemic stroke, a condition with significant unmet medical need and a large market opportunity. The company has recently announced a licensing agreement for the dermatology application of 3K3A-APC, indicating platform versatility and a strategy to de-risk and monetize its asset through partnerships. As a private company, it remains pre-revenue and is focused on advancing its clinical pipeline.

View full company profile

Therapeutic Areas

Neurology Dermatology

Other Ischemic Stroke Drugs

Drug	Company	Phase	Status
dl-3-n-Butylphthalide (NBP) Soft Capsules	cspc-pharmaceutical	Phase 3	Active (US trials with FDA orphan drug designation)
MultiStem	Athersys	Phase 3	Active (subject to funding)
IQool™ System	BrainCool	Clinical Evaluation	Evidence Generation
itMSCs + itNSCs	Stemedica Cell Technologies	Research	Active
BXT-25	BioXyTran	Preclinical	Active
Ischemic Stroke Program	CHS Pharma	Pre-clinical	Active
Ischemic Stroke Device(s)	Infinity Neuro	Pre-clinical	Active
THDG3	DeckTherapeutics	Pre-clinical	Active
Prometheus-based Gene Therapy	Remedium Bio	Pre-clinical	Active
iNstroke Catheters	iVascularU	Commercial	Active
Dual Thrombolytic Regimen (tPA + HisproUK)	Thrombolytic Science International	Phase 2	Active
Neural Stem Cell Therapy for Stroke	Neoneuron	Pre-clinical	Active